{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:17Z","timestamp":1786979897706,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Suzuki Urological Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00262-020-02533-8","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T05:02:47Z","timestamp":1583125367000},"page":"1155-1163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette\u2013Gu\u00e9rin therapy for non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-4858","authenticated-orcid":false,"given":"Masaki","family":"Shiota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ario","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Tatsugami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Uchiumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyasu","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"issue":"5","key":"2533_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"issue":"3","key":"2533_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Hern\u00e1ndez V, Kaasinen E, Palou J, Roupr\u00eat M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"issue":"3","key":"2533_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013477. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"issue":"2","key":"2533_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180\u2013183","journal-title":"J Urol"},{"issue":"1","key":"2533_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/01.ju.0000039680.90768.b3","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169(1):90\u201395. https:\/\/doi.org\/10.1097\/01.ju.0000039680.90768.b3","journal-title":"J Urol"},{"issue":"3","key":"2533_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.eururo.2005.11.010","volume":"49","author":"JA Witjes","year":"2006","unstructured":"Witjes JA, Melissen DO, Kiemeney LA (2006) Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. Eur Urol 49(3):478\u2013484. https:\/\/doi.org\/10.1016\/j.eururo.2005.11.010","journal-title":"Eur Urol"},{"issue":"16","key":"2533_CR7","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, B\u00f6hle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol 34(16):1935\u20131944. https:\/\/doi.org\/10.1200\/JCO.2015.64.4070","journal-title":"J Clin Oncol"},{"issue":"1","key":"2533_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cas.12075","volume":"104","author":"K Kawai","year":"2013","unstructured":"Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H (2013) Bacillus Calmette\u2013Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 104(1):22\u201327. https:\/\/doi.org\/10.1111\/cas.12075","journal-title":"Cancer Sci"},{"issue":"1","key":"2533_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-017-0271-0","volume":"5","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE (2017) Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(1):68. https:\/\/doi.org\/10.1186\/s40425-017-0271-0","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2533_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","volume":"101","author":"PM Visscher","year":"2017","unstructured":"Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, Yang J (2017) 10 Years of GWAS discovery: biology, function, and translation. Am J Hum Genet 101(1):5\u201322. https:\/\/doi.org\/10.1016\/j.ajhg.2017.06.005","journal-title":"Am J Hum Genet"},{"issue":"19","key":"2533_CR11","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1200\/JCO.2006.09.8897","volume":"25","author":"N Ito","year":"2007","unstructured":"Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, Kanayama H, Nose Y, Kinukawa N, Nakamura T, Jinnai N, Seki T, Takamatsu M, Masui Y, Naito S, Ogawa O (2007) STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 25(19):2785\u20132791. https:\/\/doi.org\/10.1200\/JCO.2006.09.8897","journal-title":"J Clin Oncol"},{"issue":"4","key":"2533_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.eururo.2012.09.052","volume":"63","author":"Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S; Japan Immunotherapy SNPs-Study Group for Kidney Cancer","year":"2013","unstructured":"Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S; Japan Immunotherapy SNPs-Study Group for Kidney Cancer (2013) STAT3 polymorphism can predict the response to interferon-\u03b1 therapy in patients with metastatic renal cell carcinoma. Eur Urol 63(4):745\u2013752. https:\/\/doi.org\/10.1016\/j.eururo.2012.09.052","journal-title":"Eur Urol"},{"issue":"12","key":"2533_CR13","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22(12):1435\u20131448","journal-title":"Am J Surg Pathol"},{"key":"2533_CR14","volume-title":"TNM classification of malignant tumours","author":"LH Sobin","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley, Hoboken NJ","edition":"7"},{"issue":"10","key":"2533_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/jhg.2015.68","volume":"60","author":"Y Kawai","year":"2015","unstructured":"Kawai Y, Mimori T, Kojima K, Nariai N, Danjoh I, Saito R, Yasuda J, Yamamoto M, Nagasaki M (2015) Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals. J Hum Genet 60(10):581\u2013587. https:\/\/doi.org\/10.1038\/jhg.2015.68","journal-title":"J Hum Genet"},{"issue":"3","key":"2533_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559\u2013575. https:\/\/doi.org\/10.1086\/519795","journal-title":"Am J Hum Genet"},{"issue":"8","key":"2533_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/ng.3020","volume":"46","author":"L Fachal","year":"2014","unstructured":"Fachal L, G\u00f3mez-Caama\u00f1o A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P, Kerns SL, S\u00e1nchez-Garc\u00eda M, Lobato-Busto R, Dorling L, Elliott RM, Dearnaley DP, Sydes MR, Hall E, Burnet NG, Carracedo \u00c1, Rosenstein BS, West CM, Dunning AM, Vega A (2014) A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat Genet 46(8):891\u2013894. https:\/\/doi.org\/10.1038\/ng.3020","journal-title":"Nat Genet"},{"issue":"7","key":"2533_CR18","doi-asserted-by":"publisher","first-page":"djw005","DOI":"10.1093\/jnci\/djw005","volume":"108","author":"M Shiota","year":"2016","unstructured":"Shiota M, Fujimoto N, Imada K, Yokomizo A, Itsumi M, Takeuchi A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S (2016) Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7. J Natl Cancer Inst 108(7):djw005. https:\/\/doi.org\/10.1093\/jnci\/djw005","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2533_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/annonc\/mdw646","volume":"28","author":"M Shiota","year":"2017","unstructured":"Shiota M, Fujimoto N, Itsumi M, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M (2017) Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress. Ann Oncol 28(3):569\u2013575. https:\/\/doi.org\/10.1093\/annonc\/mdw646","journal-title":"Ann Oncol"},{"issue":"6968","key":"2533_CR20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nature02168","volume":"426","author":"International HapMap Consortium","year":"2003","unstructured":"International HapMap Consortium (2003) The International HapMap Project. Nature 426(6968):789\u2013796. https:\/\/doi.org\/10.1038\/nature02168","journal-title":"Nature"},{"key":"2533_CR21","doi-asserted-by":"publisher","first-page":"9859021","DOI":"10.1155\/2016\/9859021","volume":"2016","author":"N Zhang","year":"2016","unstructured":"Zhang N, Jiang G, Liu X, Na R, Wang X, Xu J (2016) Prediction of bacillus Calmette\u2013Guerin response in patients with bladder cancer after transurethral resection of bladder tumor by using genetic variation based on genomic studies. Biomed Res Int 2016:9859021. https:\/\/doi.org\/10.1155\/2016\/9859021","journal-title":"Biomed Res Int"},{"key":"2533_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.redox.2015.08.008","volume":"6","author":"C Ryk","year":"2015","unstructured":"Ryk C, Koskela LR, Thiel T, Wiklund NP, Steineck G, Schumacher MC, de Verdier PJ (2015) Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes. Redox Biol 6:272\u2013277. https:\/\/doi.org\/10.1016\/j.redox.2015.08.008","journal-title":"Redox Biol"},{"key":"2533_CR23","doi-asserted-by":"publisher","first-page":"232609","DOI":"10.1155\/2012\/232609","volume":"2012","author":"L Lima","year":"2012","unstructured":"Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L (2012) Predictive biomarkers of bacillus Calmette\u2013Gu\u00e9rin immunotherapy response in bladder cancer: where are we now? Adv Urol 2012:232609. https:\/\/doi.org\/10.1155\/2012\/232609","journal-title":"Adv Urol"},{"issue":"3","key":"2533_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.it.2011.10.004","volume":"33","author":"M Croft","year":"2012","unstructured":"Croft M, Duan W, Choi H, Eun SY, Madireddi S, Mehta A (2012) TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol 33(3):144\u2013152. https:\/\/doi.org\/10.1016\/j.it.2011.10.004","journal-title":"Trends Immunol"},{"key":"2533_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","volume":"28","author":"M Croft","year":"2010","unstructured":"Croft M (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28:57\u201378. https:\/\/doi.org\/10.1146\/annurev-immunol-030409-101243","journal-title":"Annu Rev Immunol"},{"key":"2533_CR26","doi-asserted-by":"publisher","first-page":"35283","DOI":"10.1038\/srep35283","volume":"6","author":"N Rademacher","year":"2016","unstructured":"Rademacher N, Schmerl B, Lardong JA, Wahl MC, Shoichet SA (2016) MPP2 is a postsynaptic MAGUK scaffold protein that links SynCAM1 cell adhesion molecules to core components of the postsynaptic density. Sci Rep 6:35283. https:\/\/doi.org\/10.1038\/srep35283","journal-title":"Sci Rep"},{"issue":"6","key":"2533_CR27","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1210\/jc.2016-3766","volume":"102","author":"EA Webb","year":"2017","unstructured":"Webb EA, Balasubramanian M, Fratzl-Zelman N, Cabral WA, Titheradge H, Alsaedi A, Saraff V, Vogt J, Cole T, Stewart S, Crabtree NJ, Sargent BM, Gamsjaeger S, Paschalis EP, Roschger P, Klaushofer K, Shaw NJ, Marini JC, H\u00f6gler W (2017) Phenotypic spectrum in osteogenesis imperfecta due to mutations in TMEM38B: Unraveling a complex cellular defect. J Clin Endocrinol Metab 102(6):2019\u20132028. https:\/\/doi.org\/10.1210\/jc.2016-3766","journal-title":"J Clin Endocrinol Metab"},{"key":"2533_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Powles T, Vogelzang NJ (2017) A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev 54:58\u201367. https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.007","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2533_CR29","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0022-5347(05)00653-1","volume":"175","author":"M Decobert","year":"2006","unstructured":"Decobert M, Larue H, Bergeron A, Harel F, Pfister C, Rousseau F, Lacombe L, Fradet Y (2006) Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette\u2013Guerin immunotherapy for superficial bladder cancer. J Urol 175(4):1506\u20131511. https:\/\/doi.org\/10.1016\/S0022-5347(05)00653-1","journal-title":"J Urol"},{"issue":"3","key":"2533_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2010.11.031","volume":"59","author":"E Chiong","year":"2011","unstructured":"Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK, Kamaraj R, Tan TM, Esuvaranathan K (2011) NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette\u2013Gu\u00e9rin therapy for bladder cancer. Eur Urol 59(3):430\u2013437. https:\/\/doi.org\/10.1016\/j.eururo.2010.11.031","journal-title":"Eur Urol"},{"issue":"6","key":"2533_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1464-410X.2009.08549.x","volume":"104","author":"DK Ahirwar","year":"2009","unstructured":"Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P, Mittal RD (2009) Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette\u2013Gu\u00e9rin immunotherapy. BJU Int 104(6):867\u2013873. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08549.x","journal-title":"BJU Int"},{"issue":"5","key":"2533_CR32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bju.12844","volume":"116","author":"L Lima","year":"2015","unstructured":"Lima L, Oliveira D, Ferreira JA, Tavares A, Cruz R, Medeiros R, Santos L (2015) The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette\u2013Gu\u00e9rin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. BJU Int 116(5):753\u2013763. https:\/\/doi.org\/10.1111\/bju.12844","journal-title":"BJU Int"},{"issue":"24","key":"2533_CR33","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","volume":"23","author":"D Leibovici","year":"2005","unstructured":"Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23(24):5746\u20135756","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02533-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-020-02533-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02533-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T19:35:36Z","timestamp":1614627336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-020-02533-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["2533"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02533-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"28 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted under review board at Kyushu University (727-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}